The DOI matches its Crossref record; 31 of the 34 references it cites were found in a registry or an index.
Disease-Specific Induced Pluripotent Stem Cells.
Open accessAbstract
Tissue culture of immortal cell strains from diseased patients is an invaluable resource for medical research but is largely limited to tumor cell lines or transformed derivatives of native tissues. Here we describe the generation of induced pluripotent stem (iPS) cells from patients with a variety of genetic diseases with either Mendelian or complex inheritance; these diseases include adenosine deaminase deficiency-related severe combined immunodeficiency (ADA-SCID), Shwachman-Bodian-Diamond syndrome (SBDS), Gaucher disease (GD) type III, Duchenne (DMD) and Becker muscular dystrophy (BMD), Parkinson disease (PD), Huntington disease (HD), juvenile-onset, type 1 diabetes mellitus (JDM), Down syndrome (DS)/trisomy 21, and the carrier state of Lesch-Nyhan syndrome. Such disease-specific stem cells offer an unprecedented opportunity to recapitulate both normal and pathologic human tissue formation in vitro, thereby enabling disease investigation and drug development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The first iPSCs reprogrammed from an individual with DS were reported in 2008 (Park et al., 2008) and multiple lines have been created from multiple different individuals since then.”
From Neurodevelopment in Down syndrome: Concordance in humans and models (2022) · cites this paper as Park et al., 2008
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Induction of pluripotent stem cells from adult human fibroblasts by defined factors.
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/s0093-3619(08)70915-8 · Cited by 19,664 · cited 2×
“In contrast, introducing a set of transcription factors linked to pluripotency can directly reprogram human somatic cells to produce induced pluripotent stem (iPS) cells, a method that has been achieved by several groups worldwide (Lowry et al., 2008; Park et al., 2008b; Takahashi et al., 2007; Yu et al., 2007).”
Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R., et al. (2007) · Science · doi:10.1126/science.1151526 · Cited by 10,310 · cited 2×
“In contrast, introducing a set of transcription factors linked to pluripotency can directly reprogram human somatic cells to produce induced pluripotent stem (iPS) cells, a method that has been achieved by several groups worldwide (Lowry et al., 2008; Park et al., 2008b; Takahashi et al., 2007; Yu et al., 2007).”
Reprogramming of human somatic cells to pluripotency with defined factors
Park, I.-H., Zhao, R., West, J. A., Yabuuchi, A., Huo, H., Ince, T. A., Lerou, P. H., Lensch, M. W., & Daley, G. Q. (2008) · Nature · doi:10.1038/nature06534 · Cited by 2,436 · cited 12×
“Following 2 to 3 weeks of culture in hES cell-supporting conditions, compact refractile ES-like colonies emerged among a background of fibroblasts, as previously described (Park et al., 2008a, 2008b).”
InfluentialSelf-citationSite-directed mutagenesis by gene targeting in mouse embryo-derived stem cells
Thomas, K. R., & Capecchi, M. R. (1987) · Cell · doi:10.1016/0092-8674(87)90646-5 · Cited by 2,355 · cited 1×
“Strategies for inducing specific mutation or gene repair by homologous recombination were first established for the HPRT locus (Doetschman et al., 1987, 1988; Thomas and Capecchi, 1987).”
Murry, C. E., & Keller, G. M. (2008) · Cell · doi:10.1016/j.cell.2008.02.008 · Cited by 1,760 · cited 1×
“Human embryonic stem cells isolated from excess embryos from in vitro fertilization clinics represent an immortal propagation of pluripotent cells that theoretically can generate any cell type within the human body (Lerou et al., 2008; Murry and Keller, 2008).”
Deletion screening of the Duchenne muscular dystrophy locus via multiplex DNA amplification
Chamberlain, J. S., Gibbs, R. A., Rainer, J. E., Nguyen, P. N., & Caskey, C. T. (1988) · Nucleic Acids Research · doi:10.1093/nar/16.23.11141 · Cited by 1,271 · cited 2×
“Multiplex PCR analysis with primer sets amplifying several (but not all) intragenic intervals of the dystrophin gene (Beggs et al., 1990; Chamberlain et al., 1988) revealed the deletion of exons 45–52 in the iPS cells derived from a patient with Duchenne muscular dystrophy (DMD; Figure 1C).”
Generation of human induced pluripotent stem cells from dermal fibroblasts
Lowry, W. E., Richter, L., Yachechko, R., Pyle, A. D., Tchieu, J., Sridharan, R., Clark, A. T., & Plath, K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711983105 · Cited by 1,041 · cited 2×
“In contrast, introducing a set of transcription factors linked to pluripotency can directly reprogram human somatic cells to produce induced pluripotent stem (iPS) cells, a method that has been achieved by several groups worldwide (Lowry et al., 2008; Park et al., 2008b; Takahashi et al., 2007; Yu et al., 2007).”
Sequential Expression of Pluripotency Markers during Direct Reprogramming of Mouse Somatic Cells
Brambrink, T., Foreman, R. K., Welstead, G. G., Lengner, C. J., Wernig, M., Suh, H., & Jaenisch, R. (2008) · Cell stem cell · doi:10.1016/j.stem.2008.01.004 · Cited by 839 · cited 2×
“…from a carrier of Lesch-Nyhan syndrome using five doxycycline-inducible lentiviral vectors (OCT4, SOX2, KLF4, c-MYC, and NANOG), a strategy that has been used to isolate murine iPS cells (Brambrink et al., 2008; Stadtfeld et al., 2008) but previously had not been attempted with human somatic cells.”
Defining molecular cornerstones during fibroblast to iPS cell reprogramming in mouse
Stadtfeld, M., Maherali, N., Breault, D. T., & Hochedlinger, K. (2008) · Cell stem cell · doi:10.1016/j.stem.2008.02.001 · Cited by 823 · cited 4×
“…from a carrier of Lesch-Nyhan syndrome using five doxycycline-inducible lentiviral vectors (OCT4, SOX2, KLF4, c-MYC, and NANOG), a strategy that has been used to isolate murine iPS cells (Brambrink et al., 2008; Stadtfeld et al., 2008) but previously had not been attempted with human somatic cells.”
MethodInfluentialSelf-citationNon–cell autonomous effect of glia on motor neurons in an embryonic stem cell–based ALS model
Di Giorgio, F. P., Carrasco, M. A., Siao, M. C., Maniatis, T., & Eggan, K. (2007) · Nature Neuroscience · doi:10.1038/nn1885 · Cited by 799
Flagged first, then by citations
3 of the 34 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Hirschhorn, 1993, Two new mutations at the adenosine deaminase (ADA) locus (Q254X and del nt1050–54) unusual for not being missense mutations, Hum. Mutat., 2, 320, 10.1002/humu.1380020415 · DOI
Cited by
Sorted by citations
Items 401–500 of 1,010
Urine-Derived Stem Cells: Applications in Regenerative and Predictive Medicine
Bento, G., Shafigullina, A. K., Rizvanov, A. A., Sardão, V. A., Macedo, M. P., & Oliveira, P. J. (2020) · Cells · doi:10.3390/cells9030573 · Cited by 79
Jang, Y., Choi, J., Park, N., Kang, J., Kim, M., Kim, Y., & Ju, J. H. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0190-2 · Cited by 76
Hu, N., Corbett, G. T., Moore, S., Klyubin, I. V., O’Malley, T. T., Walsh, D. M., Livesey, F. J., & Rowan, M. J. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.04.040 · Cited by 84
“, 2012), and Ts21 (Park et al., 2008)—were generated from iPSCs according to our previously described methods (Shi et al.”
MethodInfluentialDirected Differentiation of Human Induced Pluripotent Stem Cells into Fallopian Tube Epithelium
Yucer, N., Holzapfel, M., Vogel, T. J., Lenaeus, L., Ornelas, L., Laury, A. R., Sareen, D., Barrett, R. J., Karlan, B. Y., & Svendsen, C. N. (2017) · Scientific Reports · doi:10.1038/s41598-017-05519-2 · Cited by 75
Induced pluripotent stem cell (iPSCs) and their application in immunotherapy
Jiang, Z., Han, Y., & Cao, X. (2013) · Cellular and Molecular Immunology · doi:10.1038/cmi.2013.62 · Cited by 73
Walia, B., Satija, N. K., Tripathi, R. P., & Gangenahalli, G. U. (2011) · Stem Cell Reviews and Reports · doi:10.1007/s12015-011-9279-x · Cited by 62
“iPS cell lines have already been generated from the somatic cells of patients suffering from diseases such as Gaucher’s disease, muscular dystrophy, Parkinson’s disease, Huntington disease, sickle cell anemia and more [156, 158, 159].”
BackgroundHuman pluripotent stem cells for disease modelling and drug screening
Maury, Y., Gauthier, M., Peschanski, M., & Martinat, C. (2011) · BioEssays · doi:10.1002/bies.201100071 · Cited by 72
iPSC technology to study human aging and aging-related disorders
Liu, G., Ding, Z., & Belmonte, J. C. I. (2012) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2012.08.014 · Cited by 70
Upping the ante: recent advances in direct reprogramming.
Müller, L. U. W., Daley, G., & Williams, D. A. (2009) · Molecular Therapy · doi:10.1038/mt.2009.72 · Cited by 68
Self-citationInduced pluripotent stem (iPS) cells as in vitro models of human neurogenetic disorders
Chamberlain, S. J., Li, X.-J., & Lalande, M. (2008) · Neurogenetics · doi:10.1007/s10048-008-0147-z · Cited by 68
“In fact, iPS cells have recently been generated from patient fibroblasts to model Parkinson disease, Huntington disease, Down Syndrome, Amyotrophic Lateral Sclerosis (ALS), and others [13, 14].”
BackgroundMethodNaia, L., Ly, P., Mota, S., Lopes, C., Maranga, C., Coelho, P., Gershoni-Emek, N., Ankarcrona, M., Geva, M., Hayden, M., et al. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01022-9 · Cited by 67
“Neural stem cells (NSCs) were differentiated from heterozygous human-induced pluripotent stem cells (iPSC), HD4-iPSC, with a normal (19 CAG repeats) and an expanded allele (72 CAG repeats) generated by Park and colleagues [22], generously provided by Prof.”
MethodStem cell therapy for neurological disorders
Baronica, K. B., & Friedrich, L. (2011) · Translational Neuroscience · doi:10.2478/s13380-011-0040-3 · Cited by 67
Immune regulatory cells in umbilical cord blood: T regulatory cells and mesenchymal stromal cells
Tolar, J., Hippen, K. L., & Blazar, B. R. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07781.x · Cited by 58
Stem cells and the evolving notion of cellular identity
Daley, G. Q. (2015) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2014.0376 · Cited by 111
Self-citationThe case for induced pluripotent stem cell‐derived cardiomyocytes in pharmacological screening
Khan, J. M., Lyon, A. R., & Harding, S. E. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02118.x · Cited by 66
“A number of other groups have replicated this work showing that human somatic cells can be reprogrammed to a pluripotent state by forced expression of a small set of transcription factors (Maherali et al., 2007; Okita et al., 2007; Wernig et al., 2007; Lowry et al., 2008; Park et al., 2008b).”
BackgroundModeling Huntington's disease with induced pluripotent stem cells
Kaye, J., & Finkbeiner, S. M. (2013) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2013.02.005 · Cited by 68
“Importantly, iPSC technology enables models to be created of both genetically inherited and sporadic diseases in vitro (Ebert et al., 2009; Park et al., 2008a).”
InfluentialPopescu, I. R., Nicaise, C., Liu, S., Bisch, G., Knippenberg, S., Daubie, V., Bohl, D., & Pochet, R. (2013) · Stem Cells Translational Medicine · doi:10.5966/sctm.2012-0042 · Cited by 66
Lü, H., Lim, S.-X., Leong, M. F., Narayanan, K., Toh, R. P. K., Gao, S., & Wan, A. C. A. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.09.006 · Cited by 58
Human induced pluripotent stem cells and neurodegenerative disease
Jung, Y. W., Hysolli, E., Kim, K., Tanaka, Y., & Park, I. (2012) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3283518226 · Cited by 72
“Currently, patient-derived iPSCs are being used in the development of disease-specific cellular models and drug-screening platforms [8,9].”
BackgroundSelf-citationA fluorescent rosamine compound selectively stains pluripotent stem cells.
Im, C.-N., Kang, N.-Y., Ha, H.-H., Bi, X., Lee, J. J., Park, S.-J., Lee, S.-Y.-O., Vendrell, M., Kim, Y., Lee, J.-S., et al. (2010) · Angewandte Chemie · doi:10.1002/anie.201002463 · Cited by 66
Corneal cell therapy: with iPSCs, it is no more a far-sight
Chakrabarty, K., Shetty, R., & Ghosh, A. (2018) · Stem Cell Research & Therapy · doi:10.1186/s13287-018-1036-5 · Cited by 77
Borgs, L., Peyre, E., Alix, P., Hanon, K., Grobarczyk, B., Godin, J. D., Purnelle, A., Krusy, N., Maquet, P., Lefebvre, P. P., et al. (2016) · Scientific Reports · doi:10.1038/srep33377 · Cited by 62
Converting human pluripotent stem cells into β-cells: recent advances and future challenges
Mayhew, C. N., & Wells, J. M. (2010) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0b013e3283337e1c · Cited by 60
Generation of Induced Pluripotent Stem Cells by Efficient Reprogramming of Adult Bone Marrow Cells
Kunisato, A., Wakatsuki, M., Kodama, Y., Shinba, H., Ishida, I., & Nagao, K. (2010) · Stem Cells and Development · doi:10.1089/scd.2009.0149 · Cited by 65
Jin, Z., Okamoto, S., Mandai, M., & Takahashi, M. (2009) · Journal of Genetics · doi:10.1007/s12041-009-0063-5 · Cited by 65
Fitzgerald, J. C., & Plun‐Favreau, H. (2008) · FEBS Journal · doi:10.1111/j.1742-4658.2008.06708.x · Cited by 68
The functional genomics laboratory: functional validation of genetic variants
Rodenburg, R. J. (2018) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-018-0146-7 · Cited by 83
“This has opened up new possibilities to study genetic variants in patient-derived differentiated cells in cell culture (Park et al. 2008; Onder and Daley 2012).”
BackgroundBahmad, H. F., Hadadeh, O., Chamaa, F., Cheaito, K. A., Darwish, B., Makkawi, A.-K., & Abou-Kheir, W. G. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00050 · Cited by 70
“To date, the most popular donor somatic cells are fibroblasts, being used in more than 80% of all reprogramming experiments published (González et al., 2011).”
BackgroundFibroblast sources: Where can we get them?
Fernandes, I. R., Russo, F. B., Pignatari, G. C., Evangelinellis, M. M., Tavolari, S., Muotri, A., & Beltrão-Braga, P. (2016) · Cytotechnology (Dordrecht) · doi:10.1007/s10616-014-9771-7 · Cited by 64
Using iPS Cells toward the Understanding of Parkinson’s Disease
Torrent, R., Rigotti, F., Dell’Era, P., Memo, M., Raya, Á., & Consiglio, A. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm4040548 · Cited by 65
“The first group generated PD-specific iPSC from a sporadic PD patient in 2008 [27].”
BackgroundSkeletal Muscle Tissue Engineering: Which Cell to Use?
Fishman, J., Tyraskis, A., Maghsoudlou, P., Urbani, L., Totonelli, G., Birchall, M., & de Coppi, P. (2013) · Tissue engineering. Part B, Reviews · doi:10.1089/ten.teb.2013.0120 · Cited by 64
Pluripotent stem cell-derived natural killer cells for cancer therapy
Knorr, D., & Kaufman, D. (2010) · Translational Research: The Journal of Laboratory and Clinical Medicine · doi:10.1016/j.trsl.2010.07.008 · Cited by 64
Cell Delivery: From Cell Transplantation to Organ Engineering
Soto-Gutierrez, A., Yagi, H., Uygun, B., Navarro-Alvarez, N., Uygun, K., Kobayashi, N., Yang, Y.-G., & Yarmush, M. (2010) · Cell Transplantation · doi:10.3727/096368910x508753 · Cited by 64
Olesen, M. A., Villavicencio-Tejo, F., & Quintanilla, R. A. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00308-y · Cited by 80
Stem Cell Transplantation Therapy and Neurological Disorders: Current Status and Future Perspectives
Rahman, M. M., Islam, M. R., Islam, M. T., Harun-Or-Rashid, M., Islam, M., Abdullah, S., Uddin, M., Das, S. K., Rahaman, M. S., Ahmed, M., et al. (2022) · Biology · doi:10.3390/biology11010147 · Cited by 82
“Since then, somatic cell lines derived from various species, including humans [35–37], pigs [38], mice [39], rhesus monkeys [40], marmosets [41], and sheep [42], have been successfully reprogrammed into iPSCs.”
BackgroundWu, Y., Chiu, F., Yeh, C.-S., & Kuo, H. (2019) · Open Biology · doi:10.1098/rsob.180177 · Cited by 78
Bioreactor engineering of stem cell environments
Tandon, N. M., Marolt, D., Cimetta, E., & Vunjak‐Novakovic, G. (2013) · Biotechnology Advances · doi:10.1016/j.biotechadv.2013.03.007 · Cited by 59
“A series of diseases have already been successfully modeled in vitro via reprogramming of patient cells to iPS cells followed by differentiation into disease-relevant cells and tissues: neurodegenerative diseases, haematopoietic disorders, metabolic conditions and cardiovascular pathologies (Chamberlain et al. 2008; E…”
BackgroundAssou, S., Bouckenheimer, J., & De Vos, J. (2018) · Stem Cells · doi:10.1002/stem.2797 · Cited by 81
The Promise and Challenge of Induced Pluripotent Stem Cells for Cardiovascular Applications
Youssef, A., Ross, E., Bolli, R., Pepine, C. J., Leeper, N. J., & Yang, P. C.-M. (2016) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2016.06.010 · Cited by 62
Congenital amegakaryocytic thrombocytopenia iPS cells exhibit defective MPL-mediated signaling
Hirata, S., Takayama, N., Ohnishi, R., Endo, H., Nakamura, S., Dohda, T., Nishi, M., Hamasaki, Y., Ishii, E., Kaneko, S., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64721 · Cited by 66
The p53–PUMA axis suppresses iPSC generation
Li, Y., Feng, H., Gu, H., Lewis, D. W., Yuan, Y., Zhang, L., Yu, H. M., Zhang, P., Cheng, H., Miao, W., et al. (2013) · Nature Communications · doi:10.1038/ncomms3174 · Cited by 64
Modeling Alzheimer’s disease: from past to future
Saraceno, C., Musardo, S., Marcello, E. E., Pelucchi, S., & Luca, M. D. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00077 · Cited by 62
Cellular Therapy and Induced Neuronal Replacement for Huntington's Disease
Benraiss, A., & Goldman, S. A. (2011) · Neurotherapeutics · doi:10.1007/s13311-011-0075-8 · Cited by 57
“A variety of disease-specific iPS cells, including those for HD, have been generated and have already found uses in drug screening and in the investigation of disease-specific molecular pathways [58–61].”
Mechanotransduction: Tuning Stem Cells Fate
D’Angelo, F., Tiribuzi, R., Armentano, I., Kenny, J. M., Martino, S., & Orlacchio, A. (2011) · Journal of Functional Biomaterials · doi:10.3390/jfb2020067 · Cited by 65
“in 2008 [88] showed for the first time the feasibility of generating iPS cells from fibroblasts of patients with complex genetic disorders”
BackgroundMethodReprogramming Huntington Monkey Skin Cells into Pluripotent Stem Cells
Chan, A., Cheng, P.-H., Neumann, A., & Yang, J.-J. (2010) · Cellular Reprogramming · doi:10.1089/cell.2010.0019 · Cited by 62
“…and the influence of developmental events that lead to pathologic consequences (Byrne et al., 2007; Dimos et al., 2008; Hanna et al., 2007; Lakshmipathy et al., 2007a, 2007b; Laurent et al., 2008; Muller et al., 2008; Park et al., 2008a, 2008b, 2008c; Pruszak et al., 2007; Rutllant et al., 2003).”
Progress and Promise Towards Safe Induced Pluripotent Stem Cells for Therapy
Seifinejad, A., Tabebordbar, M., Baharvand, H., Boyer, L. A., & Salekdeh, G. H. (2010) · Stem Cell Reviews and Reports · doi:10.1007/s12015-010-9121-x · Cited by 59
“Muscle skeletal DMD[22], BMD[22] Patient-derived iPSCs”
BackgroundInfluentialRegenerative medicine: a 2009 overview
Andersson, E. R., & Lendahl, U. (2009) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2009.02157.x · Cited by 17
Histone H3 lysine 27 trimethylation acts as an epigenetic barrier in porcine nuclear reprogramming
Xie, B., Zhang, H., Wei, R., Li, J., Weng, X., Kong, Q., & Liu, Z. (2015) · Reproduction · doi:10.1530/rep-15-0338 · Cited by 72
Tissue Engineering the Vascular Tree
Traoré, M. A., & George, S. C. (2017) · Tissue Engineering Part B Reviews · doi:10.1089/ten.teb.2017.0010 · Cited by 80
“The advent of stem cell technologies will facilitate the creation of patient-specific derived tissues and vascular networks.(100,101) Various protocols have been used to differentiate endothelial and smooth muscle cells from induced pluripotent stem (iPS) cells.”
Kawagoe, S., Higuchi, T., Otaka, M., Shimada, Y., Kobayashi, H., Ida, H., Ohashi, T., Okano, H. J., Nakanishi, M., & Eto, Y. (2013) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2013.06.003 · Cited by 69
“Recently, the generation of induced pluripotent stem cells has been reported from both mouse and human somatic cells with different genetic diseases using defined factors [3–9]; this advancemay provide information regarding thepathogenesis and treatment of human diseases.”
BackgroundEffective vitrification of human induced pluripotent stem cells using carboxylated ε-poly-l-lysine.
Matsumura, K., Bae, J. Y., Kim, H., & Hyon, S. (2011) · Cryobiology · doi:10.1016/j.cryobiol.2011.05.003 · Cited by 61
Autologous blood cell therapies from pluripotent stem cells
Lengerke, C., & Daley, G. (2009) · Blood reviews · doi:10.1016/j.blre.2009.10.001 · Cited by 61
Self-citationStem cell engineering for treatment of heart diseases: Potentials and challenges
Li, S., Wang, L., Jiang, H., Acevedo, J., Chang, A. C., & Loudon, W. (2009) · Cell Biology International · doi:10.1016/j.cellbi.2008.11.009 · Cited by 61
“…have taken cells from patients aged 1 month to 57 years, suffering from one of 10 conditions, including Down’s Syndrome, Parkinson’s disease, Huntington’s disease, muscular dystrophy and type1 diabetes, and used iPS to produce pluripotent, undifferentiated stem cells (Park et al., 2008a,b).”
BackgroundRecent Progress in Stem Cell Therapy for Diabetic Nephropathy
Liu, Y., & Tang, S. (2015) · Kidney Diseases · doi:10.1159/000441913 · Cited by 60
Enhancing stem cell survival in vivo for tissue repair
Hyun, J. S., Tran, M. C., Wong, V., Chung, M. T., Lo, D. D., Montoro, D. T., Wan, D. C., & Longaker, M. T. (2012) · Biotechnology Advances · doi:10.1016/j.biotechadv.2012.11.003 · Cited by 64
“Disease-specific iPS cell lines have already been created from patients suffering from amyotrophic lateral sclerosis, juvenile onset type 1 diabetes mellitus, Parkinson's disease, and spinal muscular atrophy (Dimos et al., 2008; Ebert et al., 2009; Park et al., 2008).”
BackgroundNonxenogeneic Growth and Retinal Differentiation of Human Induced Pluripotent Stem Cells
Sridhar, A., Steward, M., & Meyer, J. S. (2013) · Stem Cells Translational Medicine · doi:10.5966/sctm.2012-0101 · Cited by 58
Amniocytes can serve a dual function as a source of iPS cells and feeder layers
Anchan, R., Quaas, P., Gerami-Naini, B., Bartake, H., Griffin, A., Zhou, Y.-L., Day, D. S., Eaton, J., George, L. L., Naber, C., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq542 · Cited by 60
Adult human brain cell culture for neuroscience research
Gibbons, H. M., & Dragunow, M. (2009) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2009.12.002 · Cited by 55
Direct Reprogramming of Rat Neural Precursor Cells and Fibroblasts into Pluripotent Stem Cells
Chang, M., Kim, D., Kim, C.-H., Kang, H.-C., Yang, E., Moon, J., Ko, S., Park, J., Park, K.-S., Lee, K.-A., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009838 · Cited by 60
“Subsequent studies demonstrated that human induced pluripotent stem (hiPS) cells could be generated using the same or slightly different sets of reprogramming factors, offering the possibility to generate disease- or patientspecific stem cells [3,4,5,6,7,8,9,10].”
BackgroundRodríguez-Martín, T., Anthony, K., García-Blanco, M. A., Mansfield, S. G., Anderton, B. H., & Gallo, J. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp264 · Cited by 57
“Trans-splicing reduction of E10 inclusion on endogenous tau could be optimized in induced pluripotent stem cells derived from FTDP-17 patients, when available, after differentiation into neurons (45).”
BackgroundCell Transplantation and Gene Therapy in Parkinson's Disease
Wakeman, D. R., Dodiya, H. B., & Kordower, J. H. (2011) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20233 · Cited by 52
Cell Therapy for Parkinson’s Disease
Yasuhara, T., Kameda, M., Sasaki, T., Tajiri, N., & Date, I. (2017) · Cell Transplantation · doi:10.1177/0963689717735411 · Cited by 121
Brownjohn, P. W., Smith, J. C., Portelius, E., Serneels, L., Kvartsberg, H., Strooper, B. D., Blennow, K., Zetterberg, H., & Livesey, F. J. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.02.006 · Cited by 68
“Primary screeningandmechanistic studieswereperformedonneurons differentiated from iPSCs generated from an individual with TS21 (Park et al., 2008).”
BackgroundCell signalling pathways underlying induced pluripotent stem cell reprogramming
Hawkins, K. (2014) · World Journal of Stem Cells · doi:10.4252/wjsc.v6.i5.620 · Cited by 78
Stem cells for skeletal muscle regeneration: therapeutic potential and roadblocks
Rinaldi, F., & Perlingeiro, R. C. R. (2013) · Translational research · doi:10.1016/j.trsl.2013.11.006 · Cited by 62
“iPS cells have been shown by several investigators to behave very similarly to ES cells in terms of pluripotency[115-122], and the generation of patient-specific iPS cell lines that could be used for autologous transplantation following appropriate in vitro differentiation has attracted great interest.”
BackgroundThe Pharmacology of Regenerative Medicine
Christ, G. J., Saul, J. M., Furth, M. E., & Andersson, K. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.007393 · Cited by 63
“The generation of induced pluripotent stem (iPS) cells by genetic reprogramming of somatic cells (Takahashi and Yamanaka, 2006), for which Yamanaka shared the 2012 Nobel Prize in Physiology or Medicine, raised the ante by potentially enabling production of autologous specialized cells of any lineage for any human bein…”
BackgroundXu, X., & Zhong, Z. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2013.63 · Cited by 67
Germline development from human pluripotent stem cells toward disease modeling of infertility.
Hayashi, Y., Saitou, M., & Yamanaka, S. (2012) · Fertility and Sterility · doi:10.1016/j.fertnstert.2012.04.037 · Cited by 59
Surmacz, B., Noisa, P., Risner-Janiczek, J. R., Hui, K., Ungless, M. A., Cui, W., & Li, M. (2011) · Stem Cell Reviews and Reports · doi:10.1007/s12015-011-9298-7 · Cited by 55
“Furthermore, the rapid advances in deriving functionally equivalent induced pluripotent stem cells (iPSC) by reprogrammingpatient-derivedsomaticcelltypeswithknown or unknown disease genes raise the prospect of utilising these cells to model human diseases in vitro [ 36 , 49].”
BackgroundGeneration of Healthy Mice from Gene-Corrected Disease-Specific Induced Pluripotent Stem Cells
Wu, G., Liu, N., Rittelmeyer, I., Sharma, A. D., Sgodda, M., Zaehres, H., Bleidißel, M., Greber, B., Gentile, L., Han, D., et al. (2011) · PLoS Biology · doi:10.1371/journal.pbio.1001099 · Cited by 57
“Various human disease-specific iPS cell lines have been generated [6] either for disease modeling [7–16] or for cell transplantation in”
BackgroundGeneration of Retinal Ganglion–like Cells from Reprogrammed Mouse Fibroblasts
Chen, M., Chen, Q., Sun, X., Shen, W., Liu, B., Zhong, X., Leng, Y., Li, C., Zhang, W., Chai, F., et al. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.09-4504 · Cited by 103
“Pluripotent stem cells can be generated by reprogramming patient somatic cells, thereby avoiding immune rejection and ethical issues, and patient-tailored iPS cells will be valuable for regeneration medicine.(17,18,54) However, several obstacles must be overcome before the therapeutic application of iPS cells to human…”
BackgroundRaya, Á., Rodríguez-Pizà, I., Navarro, S., Richaud‐Patín, Y., Güenechea, G., Sánchez‐Danés, A., Consiglio, A., Bueren, J. A., & Belmonte, J. C. I. (2010) · Nature Protocols · doi:10.1038/nprot.2010.9 · Cited by 52
“has enabled the derivation of disease-specific pluripotent cells and provided valuable experimental platforms to model human diseas”
BackgroundSilencing Trisomy 21 with XIST in Neural Stem Cells Promotes Neuronal Differentiation
Czerminski, J. T., & Lawrence, J. B. (2020) · Developmental Cell · doi:10.1016/j.devcel.2019.12.015 · Cited by 95
“Daley (Park et al., 2008) and is derived from a male with Down syndrome.”
BackgroundReprogramming patient-derived cells to study the epilepsies
Parent, J. M., & Anderson, S. A. (2015) · Nature Neuroscience · doi:10.1038/nn.3944 · Cited by 53
How induced pluripotent stem cells are redefining personalized medicine
Ferreira, L. M. R., & Mostajo-Radji, M. A. (2013) · Gene · doi:10.1016/j.gene.2013.02.037 · Cited by 52
Concise Review: Patient-Derived Olfactory Stem Cells: New Models for Brain Diseases
Mackay‐Sim, A. (2012) · Stem Cells · doi:10.1002/stem.1220 · Cited by 59
Neural stem cells: mechanisms and modeling
Yao, J., Mu, Y., & Gage, F. H. (2012) · Protein & Cell · doi:10.1007/s13238-012-2033-6 · Cited by 61
“, 2007), the successful reprogramming of fibroblasts has been accomplished for a variety of neurodegenerative and neurodevelopmental diseases, such as amyotrophic lateral sclerosis (ALS), PD (Dimos et al., 2008; Park et al., 2008; Soldner et al., 2009), spinal muscular atrophy (SMA), familial dysautonomia (FD) (Ebert…”
BackgroundChoi, S., Kim, Y., Liu, H., Chaudhari, P., Ye, Z.-H., & Jang, Y.-Y. (2011) · Cell Cycle · doi:10.4161/cc.10.15.16869 · Cited by 58
A call for standardized naming and reporting of human ESC and iPSC lines.
Luong, M. X., Auerbach, J., Crook, J. M., Daheron, L., Hei, D., Lomax, G., Loring, J. F., Ludwig, T., Schlaeger, T. M., Smith, K. P., et al. (2011) · Cell Stem Cell · doi:10.1016/j.stem.2011.03.002 · Cited by 56
“Naming of Cell Lines Thecurrent lackof anamingconvention for human ESC and iPSC lines has resulted in a broad spectrum of names ranging from asinglenumber tomanyandvariedcombinations of letters, numbers, and hyphens (e.g., ‘‘60’’ and ‘‘DH1CF32-IPS2’’) (Woltjen et al., 2009;Park et al., 2008).”
BackgroundMYC Transcription Factors: Key Regulators Behind Establishment and Maintenance of Pluripotency
Smith, K. N., & Dalton, S. (2010) · Regenerative Medicine · doi:10.2217/rme.10.79 · Cited by 56
Shao, K., Koch, C., Gupta, M. K., Lin, Q., Lenz, M., Laufs, S., Denecke, B., Schmidt, M., Linke, M., Hennies, H., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2012.207 · Cited by 58
Derivation of dopaminergic neurons from pluripotent stem cells
Studer, L. (2012) · Progress in brain research · doi:10.1016/b978-0-444-59575-1.00011-9 · Cited by 80
Ronchi, S., Buccino, A., Prack, G., Kumar, S., Schröter, M., Fiscella, M., & Hierlemann, A. (2020) · bioRxiv · doi:10.1101/2020.09.02.271403 · Cited by 57
Polymer-Based Instructive Scaffolds for Endodontic Regeneration
Zein, N., Harmouch, E., Lutz, J.-C., de Grado, G. F., Kuchler‐Bopp, S., Clauss, F., Offner, D., Hua, G., Benkirane-Jessel, N., & Fioretti, F. (2019) · Materials · doi:10.3390/ma12152347 · Cited by 58
Improving single-cell cloning workflow for gene editing in human pluripotent stem cells.
Chen, Y.-H., & Pruett-Miller, S. (2018) · Stem Cell Research · doi:10.1016/j.scr.2018.08.003 · Cited by 57
“Human pluripotent stem cells, including induced pluripotent stem cells (hiPSCs) and human embryonic stem cells (hESCs), hold great promise for cell research and clinical applications (Kiskinis and Eggan, 2010; Park et al., 2008; Saha and Jaenisch, 2009).”
BackgroundCalenic, B., Greabu, M., Caruntu, C., Tănase, C., & Battino, M. (2015) · Periodontology 2000 · doi:10.1111/prd.12097 · Cited by 57
“In recent years, human induced pluripotent stem cells have generated much interest in the field of developmental biology as a result of their unique characteristics, which include the ability to renew indefinitely in in vitro conditions and to differentiate to virtually any human cell type (for extensive reviews on th…”
BackgroundChen, A. E., Borowiak, M., Sherwood, R. I., Kweudjeu, A., & Melton, D. (2013) · Development · doi:10.1242/dev.085431 · Cited by 57
“, 2009) and iPS (Maehr et al., 2009; Park et al., 2008) cells, our understanding of the necessary signals required for the complete derivation of mature β cells in vitro is still limited (Naujok et al.”
BackgroundLee, S. B., Seo, D., Choi, D., Park, K.-Y., Holczbauer, A., Marquardt, J. U., Conner, E., Factor, V., & Thorgeirsson, S. (2012) · Stem Cells · doi:10.1002/stem.1074 · Cited by 57
Thatava, T., Armstrong, A. S., Lamo, J. G. D., Edukulla, R., Khan, Y. K., Sakuma, T., Ohmine, S., Sundsbak, J. L., Harris, P. C., Kudva, Y. C., et al. (2011) · Stem Cell Research & Therapy · doi:10.1186/scrt89 · Cited by 62
Wang, B., Miyagoe-Suzuki, Y., Yada, E., Ito, N., Nishiyama, T., Nakamura, M., Ono, Y., Motohashi, N., Segawa, M., Masuda, S., et al. (2011) · PLOS Currents · doi:10.1371/currents.rrn1274 · Cited by 57
The Molecular Mechanism of Induced Pluripotency: A Two-Stage Switch
Scheper, W., & Copray, S. C. V. M. (2009) · Stem Cell Reviews and Reports · doi:10.1007/s12015-009-9077-x · Cited by 60
“A number of recent studies demonstrated that iPS cells indeed can be generated directly from human patients suffering from Parkinson’s disease, type 1 diabetes mellitus, severe combined immunodeficiency, muscular dystrophy and Down syndrome [16].”
BackgroundResultT lineage differentiation from induced pluripotent stem cells
Lei, F., Haque, R., Kaminsky, L. W., Vrana, K. E., & Song, J. J. (2009) · Cellular Immunology · doi:10.1016/j.cellimm.2009.09.005 · Cited by 56
Rissone, A., Weinacht, K. G., la Marca, G., Bishop, K., Giocaliere, E., Jagadeesh, J., Felgentreff, K., Dobbs, K., Al-Herz, W., Jones, M., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20141286 · Cited by 63
Genomic Editing Tools to Model Human Diseases with Isogenic Pluripotent Stem Cells
Kim, H. S., Bernitz, J. M., Lee, D., & Lemischka, I. R. (2014) · Stem Cells and Development · doi:10.1089/scd.2014.0167 · Cited by 57
“As iPSC generation has become more efficient, many patient-specific iPSCs have been derived to model disease [16].”
BackgroundUse of induced pluripotent stem cells to recapitulate pulmonary alveolar proteinosis pathogenesis.
Suzuki, T., Mayhew, C., Sallese, A., Chalk, C., Carey, B., Malik, P., Wood, R., & Trapnell, B. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201306-1039oc · Cited by 56
Xiong, Z.-M., LaDana, C., Wu, D., & Cao, K. (2013) · Aging · doi:10.18632/aging.100550 · Cited by 56
“To set up an in vitro cellular model of HGPS, we generated iPSCs from two HGPS primary skin fibroblast lines (HGADFN164: HGPS-1 and HGADFN155: HGPS-2, respectively) and one agematched normal fibroblast line (AG08470) by retroviral transduction of KLF4, SOX2, OCT4, and CMYC cocktails [27, 28] (See table S1 for cell lin…”
MethodTian, C., Ambroz, R., Sun, L., Wang, Y., Ma, K., Chen, Q., Zhu, B., & Zheng, J. C. (2012) · Current Molecular Medicine · doi:10.2174/156652412798889018 · Cited by 48
Safeguarding Nonhuman Primate iPS Cells With Suicide Genes
Zhong, B., Watts, K. L., Gori, J. L., Wohlfahrt, M. E., Enssle, J., Adair, J. E., & Kiem, H. (2011) · Molecular Therapy · doi:10.1038/mt.2011.51 · Cited by 56
Stem cells as a therapeutic tool for the blind: biology and future prospects
Singh, M. S., & MacLaren, R. E. (2011) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.2011.1028 · Cited by 57
The science and ethics of induced pluripotency: what will become of embryonic stem cells?
Zacharias, D. G., Nelson, T. J., Mueller, P. S., & Hook, C. (2011) · Mayo Clinic proceedings · doi:10.4065/mcp.2011.0054 · Cited by 56
Metadata
- Authors
- Park, I.-H., Arora, N., Huo, H., Maherali, N., Ahfeldt, T., Shimamura, A., Lensch, M. W., Cowan, C., Hochedlinger, K., & Daley, G. Q.
- Affiliations
- Boston Children's Hospital (US)
- Harvard University (US)
- University of Washington (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Daley, George Q.
- ORCID
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2008-09
- Volume
- 134
- Issue
- 5
- Pages
- 877-886
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC2633781
- OpenAlex
- W2157645703
- Cited by
- 2,196
- References
- 34
- Citations by year
- 2026: 20 · 2025: 32 · 2024: 38 · 2023: 51 · 2022: 62 · 2021: 75 · 2020: 89 · 2019: 73 · 2018: 71 · 2017: 108 · 2016: 125 · 2015: 144 · 2014: 139 · 2013: 204 · 2012: 272
- FWCI
- 95.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health (DP1OD000256)
- National Heart, Lung, and Blood Institute (R01HL079582)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK059279)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Keywords
- induced pluripotent stem cells, genetic disorders, Mendelian inheritance, multifactorial inheritance, ADA-SCID, Duchenne muscular dystrophy, Becker muscular dystrophy, Parkinson's disease, Huntington's disease, Down syndrome, Lesch-Nyhan syndrome, in vitro disease model, drug development
- MeSH terms
- Bone Marrow Cells, Cell Line, Fibroblasts, Humans, Karyotyping, Mutation, Genetic Diseases, Inborn, Pluripotent Stem Cells, Mesenchymal Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
